- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1970.
- Why 4/10
- BioThrax is an already-approved, marketed vaccine with no pending PDUFA date, pivotal readout, or regulatory decision in the next 12 months. The drug generates recurring government contract revenue but lacks a hard binary catalyst, capping the impact score at 4 per the rubric.
BioThrax is a mature, approved product with no pending FDA catalyst. The stock's next binary event is the Q4 2026 earnings report (likely Feb 2027), where the key question is whether Anthrax MCM revenue stabilizes after the Q3 miss and whether the CYFENDUS transition cannibalizes BioThrax further. Watch for DoD contract renewals on the $21.5M BioThrax delivery order (option periods for 2027-2028).
Price Chart
Executive Summary
BioThrax (Anthrax Vaccine Adsorbed) is a long-approved anthrax vaccine originally licensed in 1970 and manufactured by Emergent BioSolutions Inc. (NYSE: EBS). It is one of only two FDA-approved anthrax vaccines (alongside the company's own next-gen product CYFENDUS) and generates recurring revenue primarily through U.S. government contracts with the Department of Defense and BARDA. BioThrax is a mature, cash-generative product but faces internal cannibalization from CYFENDUS (approved 2023), which offers a shorter dosing schedule. The stock fell sharply after Q3 2026 earnings on Nov 2, 2026 (revenue down 52% YoY, guidance cut), though the Anthrax MCM segment itself grew. With no pending regulatory catalyst for BioThrax, the drug is a steady but declining contributor within a company undergoing restructuring and leadership transition.
How It Works
BioThrax is a vaccine that trains the immune system to recognize and neutralize anthrax bacteria. It contains filtered proteins from a weakened, non-infectious strain of Bacillus anthracis, along with aluminum hydroxide as an adjuvant to boost the immune response. It is given as an injection (intramuscular or subcutaneous) to prevent anthrax disease before or after exposure.
Trial Status
BioThrax is FDA-approved for pre-exposure prophylaxis (active immunization) and post-exposure prophylaxis of anthrax disease. It received a supplemental approval under the FDA Animal Rule in November 2015 for inhalational anthrax. A Phase 3 study (VELOCITY, NCT03877926) comparing AV7909/CYFENDUS to BioThrax was completed in 2020 with 3,689 participants.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings report (expected Feb 2027) - key indicator of Anthrax MCM revenue trajectory and BioThrax contract execution
- DoD option period decisions for the $21.5M BioThrax delivery order (2027-2028 option periods)
- Any further BARDA or DoD contract awards for BioThrax or CYFENDUS
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report